Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil
about
Modafinil as a catecholaminergic agent: empirical evidence and unanswered questionsPharmacology of hallucinations: several mechanisms for one single symptom?Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.Ketamine for treatment-resistant unipolar depression: current evidenced-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.Kappa Opioids, Salvinorin A and Major Depressive DisorderNeuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin AL-lysine as adjunctive treatment in patients with schizophrenia: a single-blinded, randomized, cross-over pilot study.Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism.Is schizophrenia a dopamine supersensitivity psychotic reaction?Ketamine and phencyclidine: the good, the bad and the unexpected.Effects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology.Salvinorin A produces cerebrovasodilation through activation of nitric oxide synthase, κ receptor, and adenosine triphosphate-sensitive potassium channel.Common variants in DRD2 are associated with sleep duration: the CARe consortiumPerspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds.Absolute abundances and affinity states of dopamine receptors in mammalian brain: A review.Ketamine in pain management.The Association of Salvia divinorum and Psychotic Disorders: A Review of the Literature and Case Series.Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research.Challenges in the development of therapeutics for narcolepsy.NMDA receptor hypofunction phase couples independent γ-oscillations in the rat visual cortex.Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical doseExposure to nicotine produces an increase in dopamine D2(High) receptors: a possible mechanism for dopamine hypersensitivity.Chemogenomics knowledgebase and systems pharmacology for hallucinogen target identification-Salvinorin A as a case study.Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat.Behavioral characterization of striatal-enriched protein tyrosine phosphatase (STEP) knockout mice.Duration of activity and mode of action of modafinil: Studies on sleep and wakefulness in humans.Total Synthesis of (-)-Salvinorin A.Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia.Modafinil improves performance in the multiple T-Maze and modifies GluR1, GluR2, D2 and NR1 receptor complex levels in the C57BL/6J mouse.Evaluation of acetylcholine, seizure activity and neuropathology following high-dose nerve agent exposure and delayed neuroprotective treatment drugs in freely moving rats.
P2860
Q21129426-CC0AAF53-0F83-4552-BEAE-38B06BD931F7Q21284720-10D7B35D-6A8B-4F4F-8DEA-7853BBFE21FBQ24620764-A06CD2F4-4B91-459D-96D7-ACFA12B60133Q27004508-971F0D1E-C505-4D4D-94A9-C0F0BD018B06Q28067851-9386DED3-25FF-42D2-AB41-994553C58C22Q28075656-30750600-4058-4FFA-8F33-40B75E31B7BBQ30467220-06A94B20-69C4-4729-A662-027C7CBA8B54Q30475497-15F2CD2C-F966-4C90-8287-70C8FC3EDB9EQ34253787-7828B54B-057F-492A-988E-5E27F7D71FBCQ34302349-CDDAE47C-D4DF-4EE1-AB32-569165E9E714Q34377871-EED04896-AEA0-440A-9EBA-48493A2ADE2CQ34480719-B8A0BB6F-C5D5-4CAD-B065-FCC942BA4F07Q35803439-4DB11EE7-B87B-482F-AF50-852913BB6F70Q36069379-75E56498-8EA4-45A7-852D-027ED4D2E1DEQ36402504-36D66DCF-4493-4B5B-9A3D-758777324D94Q37113859-D83767FD-EC20-49B8-B691-9FBB67A1E0AAQ37838858-2BE898A6-F46C-4B4F-9164-F63E5962C814Q38105649-F568F658-50FA-4A8D-8EA2-6AD2F30568B9Q38575828-490EB451-A4E0-4155-A275-94A8594FE941Q38669576-B4D708BD-C115-4199-B2B8-D4C48ADC9D8EQ38684472-506A86CC-7AA9-4B73-995B-0756E1DAFBACQ41879463-6058D895-CECC-47BE-ABBA-0E7F32978F79Q42320778-8490BB09-543F-4528-A931-0969AFE8C0D0Q42860453-CAE8DA28-19C0-4590-9ABB-1AD593290845Q43146252-18FFD4BF-46B9-472F-B876-000C8AF7F724Q46880304-2F1AE51E-FEC7-4E12-90CC-8A4ADA6572BDQ47741961-5F542CC7-D7AA-4A55-A993-872860CD7DD2Q48139080-31D01A3B-8FC6-4BA9-8EB2-09D2412F98BAQ48248296-7CC76CFA-352C-4264-81C9-6E2BE5088A36Q48262695-A03EE875-68B6-4DD1-9063-8C41646A429DQ48499494-D9B71A85-BAB0-4C1E-A72E-E94AA4EC3222Q48663292-E4EA0360-8F3D-429C-9F0A-EAC73B10B47F
P2860
Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Dopamine D2High receptors stim ...... e, salvinorin A, and modafinil
@ast
Dopamine D2High receptors stim ...... e, salvinorin A, and modafinil
@en
Dopamine D2High receptors stim ...... e, salvinorin A, and modafinil
@nl
type
label
Dopamine D2High receptors stim ...... e, salvinorin A, and modafinil
@ast
Dopamine D2High receptors stim ...... e, salvinorin A, and modafinil
@en
Dopamine D2High receptors stim ...... e, salvinorin A, and modafinil
@nl
prefLabel
Dopamine D2High receptors stim ...... e, salvinorin A, and modafinil
@ast
Dopamine D2High receptors stim ...... e, salvinorin A, and modafinil
@en
Dopamine D2High receptors stim ...... e, salvinorin A, and modafinil
@nl
P2093
P356
P1433
P1476
Dopamine D2High receptors stim ...... e, salvinorin A, and modafinil
@en
P2093
Hong-Chang Guan
Hélène Hirbec
Philip Seeman
P2860
P304
P356
10.1002/SYN.20647
P407
P577
2009-08-01T00:00:00Z